Loading...
•
Mar 31, 2024
LifeStance Q1 2024 Earnings Report
LifeStance's Q1 2024 performance was marked by strong revenue growth and margin expansion.
Key Takeaways
LifeStance Health Group reported a 19% increase in revenue to $300.4 million for Q1 2024. The clinician base grew by 15% to 6,866. The company is reiterating its full-year revenue guidance of $1.19 billion to $1.24 billion and raising its Adjusted EBITDA expectations to $88 to $98 million.
Revenue increased by 19% to $300.4 million.
The clinician base increased by 15% to 6,866 clinicians.
Net loss was $21.1 million, primarily driven by stock-based compensation.
Adjusted EBITDA increased to $27.7 million.
Forward Guidance
LifeStance is reiterating its full-year revenue guidance of $1.19 billion to $1.24 billion and raising its Adjusted EBITDA expectations to $88 to $98 million. The company also expects total revenue of $297 to $315 million, Center Margin of $85 to $97 million, and Adjusted EBITDA of $20 to $26 million for the second quarter of 2024.
Positive Outlook
- Reiterating full year revenue of $1.19 billion to $1.24 billion.
- Raising Center Margin to $353 to $373 million.
- Raising Adjusted EBITDA to $88 to $98 million.
- Continue to expect to generate positive Free Cash Flow for the full year.
- Expect total revenue of $297 to $315 million for Q2 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...